ArticleCancer letters2007
Bombesin induces angiogenesis and neuroblastoma growth.
Article in Cancer letters, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Peptidergic Systems and Neuroblastoma.International journal of molecular sciences · 2025Review
- Cervical cancer-produced neuromedin-B reprograms Schwann cells to initiate perineural invasion.Cell death & disease · 2024Article
- Migration, invasion, and metastasis are mediated byFrontiers in oncology · 2024Article
- Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.International journal of molecular sciences · 2023Review
- Application of Alanine Scanning to Determination of Amino Acids Essential for Peptide Adsorption at the Solid/Solution Interface and Binding to the Receptor: Surface-Enhanced Raman/Infrared Spectroscopy versus Bioactivity Assays.Journal of medicinal chemistry · 2021Article
- Glucocorticoid Receptor β (GRβ): Beyond Its Dominant-Negative Function.International journal of molecular sciences · 2021Review
- Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.Frontiers in endocrinology · 2021Review
- Article
- Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma.Oncotarget · 2017Article
- Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.Oncotarget · 2017Article
- Identification of pathogenic genes and upstream regulators in age-related macular degeneration.BMC ophthalmology · 2017Article
- Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.Expert opinion on therapeutic targets · 2016Review
- Antioxidant inhibition of steady-state reactive oxygen species and cell growth in neuroblastoma.Surgery · 2015Article
- Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.Surgery · 2015Article
- Article
- Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells.Autophagy · 2013Article
- Article
- Integrin β1 is critical for gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion.Surgery · 2013Article
- Autophagy mediates paracrine regulation of vascular endothelial cells.Laboratory investigation; a journal of technical methods and pathology · 2013Article
- Magneto-Fluorescent Carbon Nanotube-Mediated siRNA for Gastrin-Releasing Peptide Receptor Silencing in Neuroblastoma.RSC advances · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Gastrin-releasing peptide (GRP), the mammalian equivalent of bombesin (BBS), is a trophic factor for highly vascular neuroblastomas; its mechanisms of action in vivo are unknown. We sought to determine the effects of BBS on the growth of neuroblastoma xenografts and on angiogenesis. BBS significantly increased the growth of SK-N-SH and BE(2)-C human neuroblastomas; tumors demonstrated increased expression of angiogenic markers, PECAM-1 and VEGF, as well as phosphorylated (p)-Akt levels. RC-3095, a BBS/GRP antagonist, attenuated BBS-stimulated tumor growth and angiogenesis in vivo. GRP or GRPR silencing significantly inhibited VEGF as well as p-Akt and p-mTOR expression in vitro. Our findings demonstrate that BBS stimulates neuroblastoma growth and the expression of angiogenic markers. Importantly, these findings suggest that novel therapeutic agents, targeting BBS-mediated angiogenesis, may be useful adjuncts in patients with advanced-stage neuroblastomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.